Application, page-21

Thanks Edski1. There should be no doubt this market has and will continue to attract a lot of R&D given the addressable market. This Cellular Therapy is certainly worth keeping an eye on as it requires harvesting ones own cells and then re-implanting. I would note, however, there is significant research available that show this manufacturing process is not particularly scalable and so the cost of care will often be multiples of alternatives, including what PAR is proposing. In fact in some cases it can be cheaper to just have a complete joint replacement.